Opinion|Videos|November 26, 2024
Beyond Hot Flashes: The Importance of Sleep in Menopause Management
Key Takeaways
- Sleep disturbances in menopause are independent symptoms, impacting mood, cardiovascular health, and Alzheimer's risk.
- Elinzanetant may improve sleep quality in menopausal women, addressing a critical aspect of menopause management.
Panelists discuss the importance of addressing sleep disturbances in menopause management, even in the absence of vasomotor symptoms (VMS), and explore how emerging research on elinzanetant could impact sleep quality and its links to mood disorders, cardiovascular disease, and Alzheimer disease, while also contemplating the potential shift in the treatment paradigm for VMS with the introduction of new neurokinin-targeted therapies as either standard of care or in combination with other treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) Sleep has been identified as an independent symptom from hot flashes. With the emerging research regarding the use of elinzanetant to combat sleep disturbances associated with menopause [such as anticipated data from the NIRVANA trial], how important is it to address sleep as part of menopause management, even in the absence of vasomotor symptoms, and how is sleep quality linked to other complications such as mood disorders, cardiovascular disease, and Alzheimer disease?
- What role do you anticipate elinzanetant to have in this space?
- (FIFFICK) How do you anticipate the treatment paradigm of VMS associated with menopause to shift with the advent of these new neurokinin-targeted therapies?
- Please discuss your thoughts on whether they’ll become a new standard of care, and if you anticipate them being used as monotherapy vs combination therapy.
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
4
Across the US, Obesity Care Still Lacks an Owner
5